Arseus on track for IPO

Arseus: credit facilities after IPO assured

Arseus is targeting its IPO for 2007. Arseus is ready to assume the consolidator role in the growing, fragmented Professional Health market in Europe.

The Initial Public Offering of Arseus will be guided by an international bank consortium, with UBS and KBC Securities acting as Global Coordinators and Joint Bookrunners, and with Bank Degroof, ING Belgium and Kempen.

Arseus has closed a EUR 200 million revolving credit facility agreement in anticipation of its Initial Public Offering (IPO). The agreement will enter into force upon realisation of the IPO. Its tenor is five years with the possibility of extending it to seven years.

After the IPO is completed, it is the intention to appropriate a part of this credit facility to replace the current financial debts of Arseus to Omega Pharma. However, a significant amount will remain available to Arseus for the implementation of its buy-and-build strategy.

The agreement has been closed in a 'club deal' structure, involving ING (facilitator), Fortis, KBC, Commerzbank and Dexia. This agreement and the competitive interest rates that have been granted, clearly express the confidence that each of the participating credit institutions has in Arseus.